Risk of Death and Cardiovascular Events in Initially Healthy Women With New-Onset Atrial Fibrillation | Atrial Fibrillation | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Go AS, Hylek EM, Phillips KA,  et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.  JAMA. 2001;285(18):2370-237511343485PubMedGoogle ScholarCrossref
Miyasaka Y, Barnes ME, Gersh BJ,  et al.  Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.  Circulation. 2006;114(2):119-12516818816PubMedGoogle ScholarCrossref
Wolf PA, Benjamin EJ, Belanger AJ, Kannel WB, Levy D, D’Agostino RB. Secular trends in the prevalence of atrial fibrillation: the Framingham Study.  Am Heart J. 1996;131(4):790-7958721656PubMedGoogle ScholarCrossref
Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study: the Rotterdam Study.  Stroke. 1997;28(2):316-3219040682PubMedGoogle ScholarCrossref
Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study.  Am J Med. 2002;113(5):359-36412401529PubMedGoogle ScholarCrossref
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.  Stroke. 1991;22(8):983-9881866765PubMedGoogle ScholarCrossref
Wang TJ, Larson MG, Levy D,  et al.  Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study.  Circulation. 2003;107(23):2920-292512771006PubMedGoogle ScholarCrossref
Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study.  Circulation. 1998;98(10):946-9529737513PubMedGoogle ScholarCrossref
Friberg J, Scharling H, Gadsbøll N, Truelsen T, Jensen GB.Copenhagen City Heart Study.  Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women vs men (the Copenhagen City Heart Study).  Am J Cardiol. 2004;94(7):889-89415464671PubMedGoogle ScholarCrossref
Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-up Study.  Am J Med. 1995;98(5):476-4847733127PubMedGoogle ScholarCrossref
Miyasaka Y, Barnes ME, Bailey KR,  et al.  Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study.  J Am Coll Cardiol. 2007;49(9):986-99217336723PubMedGoogle ScholarCrossref
Jahangir A, Lee V, Friedman PA,  et al.  Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study.  Circulation. 2007;115(24):3050-305617548732PubMedGoogle ScholarCrossref
Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE. Baseline characteristics of participants in the Women's Health Study.  J Womens Health Gend Based Med. 2000;9(1):19-2710718501PubMedGoogle ScholarCrossref
Ridker PM, Cook NR, Lee IM,  et al.  A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.  N Engl J Med. 2005;352(13):1293-130415753114PubMedGoogle ScholarCrossref
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.  JAMA. 2001;285(22):2864-287011401607PubMedGoogle ScholarCrossref
Conen D, Tedrow UB, Cook NR, Moorthy MV, Buring JE, Albert CM. Alcohol consumption and risk of incident atrial fibrillation in women.  JAMA. 2008;300(21):2489-249619050192PubMedGoogle ScholarCrossref
Fuster V, Rydén LE, Cannom DS,  et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation.  Circulation. 2006;114(7):e257-e35416908781PubMedGoogle ScholarCrossref
McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham Study.  N Engl J Med. 1971;285(26):1441-14465122894PubMedGoogle ScholarCrossref
Fried LP, Borhani NO, Enright P,  et al.  The Cardiovascular Health Study: design and rationale.  Ann Epidemiol. 1991;1(3):263-2761669507PubMedGoogle ScholarCrossref
Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions.  Am J Public Health. 1998;88(1):15-199584027PubMedGoogle ScholarCrossref
Nieuwlaat R, Capucci A, Camm AJ,  et al; European Heart Survey Investigators.  Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation.  Eur Heart J. 2005;26(22):2422-243416204266PubMedGoogle ScholarCrossref
Vidaillet H, Granada JF, Chyou PH,  et al.  A population-based study of mortality among patients with atrial fibrillation or flutter.  Am J Med. 2002;113(5):365-37012401530PubMedGoogle ScholarCrossref
Wang TJ, Massaro JM, Levy D,  et al.  A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study.  JAMA. 2003;290(8):1049-105612941677PubMedGoogle ScholarCrossref
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.  Ann Intern Med. 2007;146(12):857-86717577005PubMedGoogle ScholarCrossref
Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.  Lancet. 2006;368(9535):581-58816905022PubMedGoogle ScholarCrossref
Turnbull F.Blood Pressure Lowering Treatment Trialists' Collaboration.  Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.  Lancet. 2003;362(9395):1527-153514615107PubMedGoogle ScholarCrossref
Di Pasquale G, Casella G. Antithrombotic strategies for atrial fibrillation: on the threshold of changes? yes.  J Thromb Haemost. 2005;3(3):428-43215748227PubMedGoogle ScholarCrossref
Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women.  Circulation. 2009;119(16):2146-215219364977PubMedGoogle ScholarCrossref
Tedrow UB, Conen D, Ridker PM,  et al.  The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's Health Study).  J Am Coll Cardiol. 2010;55(21):2319-232720488302PubMedGoogle ScholarCrossref
Wang TJ, Parise H, Levy D,  et al.  Obesity and the risk of new-onset atrial fibrillation.  JAMA. 2004;292(20):2471-247715562125PubMedGoogle ScholarCrossref
Friberg L, Hammar N, Pettersson H, Rosenqvist M. Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF).  Eur Heart J. 2007;28(19):2346-235317670754PubMedGoogle ScholarCrossref
Keating RJ, Gersh BJ, Hodge DO,  et al.  Effect of atrial fibrillation pattern on survival in a community-based cohort.  Am J Cardiol. 2005;96(10):1420-142416275191PubMedGoogle ScholarCrossref
Mukamal KJ, Tolstrup JS, Friberg J, Jensen G, Grønbaek M. Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study.  Circulation. 2005;112(12):1736-174216157768PubMedGoogle ScholarCrossref
Psaty BM, Manolio TA, Kuller LH,  et al.  Incidence of and risk factors for atrial fibrillation in older adults.  Circulation. 1997;96(7):2455-24619337224PubMedGoogle ScholarCrossref
Original Contribution
May 25, 2011

Risk of Death and Cardiovascular Events in Initially Healthy Women With New-Onset Atrial Fibrillation

Author Affiliations

Author Affiliations: Department of Medicine, University Hospital, Basel, Switzerland (Dr Conen); Center for Arrhythmia Prevention (Drs Conen, Tedrow, and Albert), Division of Preventive Medicine (Drs Conen, Chae, Glynn, Everett, Buring, and Albert), and Cardiovascular Division (Drs Tedrow, Everett, and Albert), Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, and Cardiology Division, Massachusetts General Hospital, Harvard Medical School (Dr Chae), Boston, Massachusetts.

JAMA. 2011;305(20):2080-2087. doi:10.1001/jama.2011.659

Context The risks associated with new-onset atrial fibrillation (AF) among middle-aged women and populations with a low comorbidity burden are poorly defined.

Objectives To examine the association between incident AF and mortality in initially healthy women and to evaluate the influence of associated cardiovascular comorbidities on risk.

Design, Setting, and Participants Between 1993 and March 16, 2010, 34 722 women participating in the Women's Health Study underwent prospective follow-up. Participants were 95% white, older than 45 years (median, 53 [interquartile range {IQR}, 49-59] years), and free of AF and cardiovascular disease at baseline. Cox proportional hazards models with time-varying covariates were used to determine the risk of events among women with incident AF. Secondary analyses were performed among women with paroxysmal AF.

Main Outcome Measures Primary outcomes included all-cause, cardiovascular, and noncardiovascular mortality. Secondary outcomes included stroke, congestive heart failure, and myocardial infarction.

Results During a median follow-up of 15.4 (IQR, 14.7-15.8) years, 1011 women developed AF. Incidence rates per 1000 person-years among women with and without AF were 10.8 (95% confidence interval [CI], 8.1-13.5) and 3.1 (95% CI, 2.9-3.2) for all-cause mortality, 4.3 (95% CI, 2.6-6.0) and 0.57 (95% CI, 0.5-0.6) for cardiovascular mortality, and 6.5 (95% CI, 4.4-8.6) and 2.5 (95% CI, 2.4-2.6) for noncardiovascular mortality, respectively. In multivariable models, hazard ratios (HRs) of new-onset AF for all-cause, cardiovascular, and noncardiovascular mortality were 2.14 (95% CI, 1.64-2.77), 4.18 (95% CI, 2.69-6.51), and 1.66 (95% CI, 1.19-2.30), respectively. Adjustment for nonfatal cardiovascular events potentially on the causal pathway to death attenuated these risks, but incident AF remained associated with all mortality components (all-cause: HR, 1.70 [95% CI, 1.30-2.22]; cardiovascular: HR, 2.57 [95% CI, 1.63-4.07]; and noncardiovascular: HR, 1.42 [95% CI, 1.02-1.98]). Among women with paroxysmal AF (n = 656), the increase in mortality risk was limited to cardiovascular causes (HR, 2.94; 95% CI, 1.55-5.59).

Conclusion Among a group of healthy women, new-onset AF was independently associated with all-cause, cardiovascular, and noncardiovascular mortality, with some of the risk potentially explained by nonfatal cardiovascular events.